King & Spalding is advising HeartFlow Holding, Inc. in connection with its pending business combination transaction with Longview Acquisition Corp. II (NYSE: LGV), a special purpose acquisition company (SPAC). The transaction provides a pro forma enterprise value of $2.4 billion, with an estimated $400 million in cash to be available at closing for growth capital, product development and general corporate purposes. Upon completion of the transaction, which is expected in Q4 2021, the combined company will operate as HeartFlow Group, Inc. and is expected to be listed on the New York Stock Exchange under the symbol “HFLO.”
HeartFlow is the leader in revolutionizing precision heart care. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients.
The King & Spalding team advising Heartflow on this transaction includes Laura Bushnell (SVO), Tim Fesenmyer (NYC), Keith Townsend (ATL), Michael Hamilton (HOU), Jamie McMullin (CHI), Kevin Manz (NYC), DK Kim (NYC), Chelsea Vernon (HOU), Todd Amdor (SVO), Shahla Hazratjee (HOU), Stephen Hong (NYC), Sophia Armstrong (SVO) and Min Cho (NYC).